- Home
- HGBL vs INZY Comparison
HGBL vs INZY Comparison
Compare HGBL & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGBL
- INZY
- Stock Information
- Founded
- HGBL 1937
- INZY 2015
- Country
- HGBL United States
- INZY United States
- Employees
- HGBL N/A
- INZY N/A
- Industry
- HGBL Business Services
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- HGBL Consumer Discretionary
- INZY Health Care
- Exchange
- HGBL Nasdaq
- INZY Nasdaq
- Market Cap
- HGBL 72.3M
- INZY 64.9M
- IPO Year
- HGBL N/A
- INZY 2020
- Fundamental
- Price
- HGBL $2.05
- INZY $1.15
- Analyst Decision
- HGBL Strong Buy
- INZY Strong Buy
- Analyst Count
- HGBL 1
- INZY 9
- Target Price
- HGBL $4.00
- INZY $17.22
- AVG Volume (30 Days)
- HGBL 61.7K
- INZY 1.1M
- Earning Date
- HGBL 05-08-2025
- INZY 05-20-2025
- Dividend Yield
- HGBL N/A
- INZY N/A
- EPS Growth
- HGBL N/A
- INZY N/A
- EPS
- HGBL 0.14
- INZY N/A
- Revenue
- HGBL $45,361,000.00
- INZY N/A
- Revenue This Year
- HGBL $10.82
- INZY N/A
- Revenue Next Year
- HGBL $15.17
- INZY N/A
- P/E Ratio
- HGBL $14.79
- INZY N/A
- Revenue Growth
- HGBL N/A
- INZY N/A
- 52 Week Low
- HGBL $1.52
- INZY $0.72
- 52 Week High
- HGBL $2.74
- INZY $6.24
- Technical
- Relative Strength Index (RSI)
- HGBL 51.34
- INZY 50.96
- Support Level
- HGBL $1.96
- INZY $1.18
- Resistance Level
- HGBL $2.07
- INZY $1.63
- Average True Range (ATR)
- HGBL 0.08
- INZY 0.20
- MACD
- HGBL 0.01
- INZY 0.02
- Stochastic Oscillator
- HGBL 50.00
- INZY 23.66
About HGBL Heritage Global Inc.
Heritage Global Inc values and monetizes industrial and financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. It aids in facilitating the economy by diverting useful industrial assets from landfills and operating a supply chain by overseeing the post-sale account activity of financial assets. The group operates in four segments namely Auction and Liquidation; Refurbishment and Resale; Brokerage and Specialty Lending. It generates maximum revenue from the Auction and Liquidation segment. The Auction and Liquidation segment, through HGP, operates as a full-service auction, appraisal, and asset advisory firm, including the acquisition of turnkey manufacturing facilities and used industrial machinery and equipment.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.